Illumina Accuses Life Technologies of Infringing Patent

Illumina Inc. (ILMN), whose genetic analysis tools are used in disease research and drug development, accused Life Technologies Corp. (LIFE) of infringing one of its patents.

Life Technologies’ Ion Personal Genome Machine and Ion OneTouch System infringe Illumina’s patent for a method of “making and decoding of array sensors with microspheres,” Illumina said in a complaint filed yesterday in federal court in San Diego. The company seeks a court order stopping the alleged infringement and unspecified damages.

“Defendants’ infringing acts are willful in that they have knowledge of Illumina’s rights under the ‘431 Patent, but have continued to infringe, and actively induce and contribute to infringement by others,” lawyers for San Diego-based Illumina said in the complaint.

Mauricio Minotta, a spokesman for Carlsbad, California- based Life Technologies, didn’t immediately return a call to his office seeking comment on the complaint.

Life Technologies said in a Dec. 9 statement that its Ion Personal Genome Machine in June solved Europe’s E. coli outbreak by sequencing the bacteria’s DNA in two hours. The machine is the first of its kind that translates chemical information into digital data, the company said in the release.

The case is Illumina v. Life Technologies, 11-3022, U.S. District Court, Southern District of California (San Diego).

To contact the reporter on this story: Edvard Pettersson in Los Angeles at epettersson@bloomberg.net

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.